Adverse Events Reported by Postmenopausal Women in Controlled Trials With Raloxifene

Obstetrics and Gynecology

Volumn 93, Issue 4, 1999, Pages 558-565

  Davies, Graham C ^a   Huster, William J ^a   Lu, Yili ^a   Plouffe, Leo ^a   Lakshmanan, Mark ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; PREMPAK; RALOXIFENE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; DYSPAREUNIA; ENDOMETRIUM CANCER; FEMALE; FLATULENCE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LEG CRAMP; MAJOR CLINICAL STUDY; MASTALGIA; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VAGINA ATROPHY; VAGINA BLEEDING; VAGINITIS;

ADULT; AGED; BREAST DISEASES; ESTROGEN ANTAGONISTS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; INCIDENCE; MIDDLE AGED; PAIN; PIPERIDINES; POSTMENOPAUSE; RALOXIFENE; UTERINE HEMORRHAGE;

EID: 0033013227     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/00006250-199904000-00017     Document Type: Article

References (24)

1. Compston JE. Hormone replacement therapy for osteoporosis: Clinical and pathophysiological aspects. Reprod Med Rev 1994;3:209-24.
2. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998;19:55-72.
3. Paganini-Hill A. Does estrogen replacement therapy protect against Alzheimer's disease? Osteoporosis Int 1997;1(Suppl):S12-7.
4. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
5. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia. JAMA 1998;279:688-95.
6. Rozenberg S, Vandromme J, Kroll M, Pastijn A, Liebens F. Compliance to hormone replacement therapy. Int J Fertil Menopausal Stud 1995;40(Suppl 1):23-32.
7. Rees MC. The need to improve compliance to HRT. Br J Obstet Gynaecol 1997;104(Suppl 16):1-3.
8. Mitlak BH, Cohen FJ. In search of optimal long-term female hormone replacement: The potential of selective estrogen receptor modulators. Hormone Res 1997;48:155-63.
9. Tomas E, Kauppila A, Blanco G, Apaja-Sarkkinen M, Laatikainen T. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 1995;59:261-6.
10. Delmas P, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;237:1641-7.
11. Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK, et al. Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial. J Bone Miner Res 1998;13:1747-54.
12. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effect of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-51.
13. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCI: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996;11:835-42.
14. Landis RJ, Heyman ER, Koch CG. Average partial association in three-way contingency tables: A review and discussion of alternative tests. Int Stat Rev 1978;46:237-54.
15. Pocock SJ, Geller NL, Tsiatis AA. The analysis of multiple endpoints in clinical trials. Biometrics 1987;43:487-98.
16. Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol 1977;4:31-47.
17. Formosa M, Brincat MP, Cardoza LD, Studd JWW. Collagen—the significance in skin, bones, and bladder. In: Lobo RA, ed. Treatment of the postmenopausal women. Basic and clinical aspects. New York, NY: Raven Press, 1994:143-51.
18. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 1988;13:345-57.
19. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992;17:485-95.
20. Ditkoff EC, Crary WG, Cristo M, Lobo RA. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol 1991;78:991-5.
21. Polo-Kantola P, Portin R, Polo O, Helenius H, Irjala K, Erkkola R. The effect of short-term estrogen replacement therapy on cognition: A randomized, double-blind, cross-over trial in postmenopausal women. Obstet Gynecol 1998;91:459-66.
22. Nickelsen T, Lufkin EG, Riggs BL, Cox DA, Crook TH. Raloxifene hydrochloride, a selective estrogen receptor modulator: Safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology, in press.
23. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348:981-3.
24. Barrett-Connor E, Wenger NK, Grady D, Mosca L, Collins P, Kornitzter M, et al. Hormone and nonhormone therapy for the maintenance of postmenopausal health: The need for randomized controlled trials of estrogen and raloxifene. J Womens Health 1998;7:839-47.